» Articles » PMID: 31396074

Neuropsychiatric Symptoms As Predictors of Clinical Course in Neurodegeneration. A Longitudinal Study

Overview
Specialty Geriatrics
Date 2019 Aug 10
PMID 31396074
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

: To study the extent to which neuropsychiatric symptoms (NPS) influence the cognitive and functional decline in frontotemporal degeneration (FTD) and Alzheimer's disease (AD). : We assessed the progression of NPS and their influence on cognitive and functional progression in a group of FTD ( = 36) and AD patients ( = 47) at two different stages of the disease (2.5 years). A standardized scale was used to assess NPS-the Columbia University Scale for Psychopathology in Alzheimer's Disease (CUSPAD)-which tracks different symptoms including depression, psychotic symptoms, as well as sleep and conduct problems. In addition, in a subsample of patients (AD = 14 and FTD = 14), we analyzed another group of NPS by using the Neuropsychiatric Inventory (NPI). Cognitive declines were tracked by using the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE), while functionality was tracked by using the Lawton scale and the Barthel Index. : The presence of NPS impacts cognitive and functional decline in both groups of patients 2.5 years after disease onset. However, we observed a dissociable profile of the affectation of NPS in each group. In the AD group, results indicate that the progression of depressive symptoms and sleep problems predict cognitive and functional decline. In contrast, the progression of a mixed group of NPS, including conduct problems and delusions, predicts cognitive and functional decline in FTD. : The presence of NPS has a critical impact on the prediction of cognitive decline in FTD and AD patients after 2.5 years of disease progression. Our results demonstrate the importance of assessing different types of NPS in neurodegenerative disorders which, in turn, predict disease progression. Future studies should assess the role of NPS in predicting different neurocognitive pathways and in neurodegeneration.

Citing Articles

Modifiable risk factors and symptom progression in dementia over up to 8 years-Results of the DelpHi-MV trial.

Blotenberg I, Wittstrom F, Michalowsky B, Platen M, Wucherer D, Teipel S Alzheimers Dement (Amst). 2025; 17(1):e70050.

PMID: 39811699 PMC: 11730075. DOI: 10.1002/dad2.70050.


Effectiveness of psychological therapies for depression and anxiety in atypical dementia.

El Baou C, Saunders R, Buckman J, Richards M, Cooper C, Marchant N Alzheimers Dement. 2024; 20(12):8844-8854.

PMID: 39439362 PMC: 11667512. DOI: 10.1002/alz.14332.


Neuropsychiatric Symptom Profile in Alzheimer's Disease and Their Relationship With Functional Decline.

Zhu C, Schneider L, Elder G, Soleimani L, Grossman H, Aloysi A Am J Geriatr Psychiatry. 2024; 32(12):1402-1416.

PMID: 39013750 PMC: 11524781. DOI: 10.1016/j.jagp.2024.06.005.


The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials.

Fieldhouse J, van Paassen D, van Engelen M, de Boer S, Hartog W, Braak S Front Aging Neurosci. 2024; 16:1382593.

PMID: 38784446 PMC: 11112081. DOI: 10.3389/fnagi.2024.1382593.


Specific neuropsychiatric symptoms are associated with functional decline trajectories in Alzheimer's disease and Lewy body dementia: a five-year follow-up study.

Borda M, Bronnick K, Garcia-Cifuentes E, Jaramillo-Jimenez A, Reyes-Ortiz C, Patricio-Baldera J Front Med (Lausanne). 2023; 10:1267060.

PMID: 37915329 PMC: 10616879. DOI: 10.3389/fmed.2023.1267060.


References
1.
Doody R, Massman P, Dunn J . A method for estimating progression rates in Alzheimer disease. Arch Neurol. 2001; 58(3):449-54. DOI: 10.1001/archneur.58.3.449. View

2.
Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

3.
Wilson R, Barnes L, Mendes de Leon C, Aggarwal N, Schneider J, Bach J . Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology. 2002; 59(3):364-70. DOI: 10.1212/wnl.59.3.364. View

4.
MAHONEY F, BARTHEL D . FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md State Med J. 1965; 14:61-5. View

5.
Devanand D, Miller L, Richards M, Marder K, Bell K, Mayeux R . The Columbia University Scale for Psychopathology in Alzheimer's disease. Arch Neurol. 1992; 49(4):371-6. DOI: 10.1001/archneur.1992.00530280051022. View